Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1

Abstract: Talquetamab is the first approved GPRC5D-targeting bispecific antibody for the treatment of relapsed/refractory multiple myeloma (RRMM), based on results from the phase 1/2 MonumenTAL-1 study. We report the infection profile among patients treated with talquetamab in MonumenTAL-1. Patients...

Description complète

Détails bibliographiques

Auteurs principaux:	Carolina Schinke, Paula Rodriguez-Otero, Niels W. C. J. van de Donk, Brea Lipe, Noa Lavi, Leo Rasche, Samir Parekh, Oliver Van Oekelen, Deeksha Vishwamitra, Sheri Skerget, Diana Cortes-Selva, Raluca Verona, Brandi Hilder, Tara Masterson, Michela Campagna, Sheetal Khedkar, Thomas Renaud, Jaszianne Tolbert, Colleen Kane, Kathleen S. Gray, Ibrahim Saber, Christoph Heuck, Ajai Chari
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2025-11-01
Collection:	Blood Advances
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2473952925005312
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!